HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arnold won’t be back

This article was originally published in The Tan Sheet

Executive Summary

California Gov. Arnold Schwarzenegger (R) has relinquished his title as executive editor and is foregoing his salary for Flex and Muscle & Fitness magazines, his office announces July 15. His role presents a conflict of interest because the publications receive ad revenue from dietary supplement firms, the state's Democratic Party maintained in charges filed publicly with the Fair Political Practices Commission June 19. Schwarzenegger vetoed a 2004 bill by state Sen. Jackie Speier (D) that would have required the state health department create a list of banned supplements (1"The Tan Sheet" Oct. 18, 2004, p. 18)...

You may also be interested in...



Arnold Says “Hasta La Vista, Baby” To Health Department Supplement List

California schools will not be barred from accepting scholarships from companies that manufacture dietary supplements, following Governor Arnold Schwarzenegger's veto of a bill that would have authorized the state health department to create a list of banned supplements

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel